Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vor Biopharma (VOR)
NASDAQ:VOR
Holding VOR?
Track your performance easily
VOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.63 - $2.50
Previous CloseN/A
Volume424.02K
Average Volume (3M)972.22K
Market Cap
$100.61M
Enterprise Value$17.97M
Total Cash (Recent Filing)$929.00K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Mar 20, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding68,673,615
10 Day Avg. Volume607,313
30 Day Avg. Volume972,218
Standard Deviation0.19
R-Squared0.02
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$12.58Price Target Upside761.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Vor Biopharma News
PremiumCompany Announcements
Vor Biopharma Strengthens Board with New Appointment
PremiumCompany Announcements
Vor Biopharma Secures $55.6M for Cancer Therapy Trials
Bulls Say, Bears Say
Bulls Say
Clinical ProgressFDA does not require additional data to start the Phase III trial and agreed with VOR on its design.
Financial StrategyVor Biopharma addressed the cash overhang with a $56M PIPE, extending the runway to YE25.
Therapeutic EfficacyTrem-cel continues to demonstrate high engraftment rate, shielding from MYLOTARG on-target toxicity with a broader therapeutic window, and early evidence of improved relapse free survival.
Bears Say
Financial PerformanceProjected to have no revenues and a net loss of $1.65 per share, raising concerns about the company's financial health.
Financial RisksReducing price target to account for risk associated with potential dilution, suggesting investor caution regarding future share value.
Stock ValuationLowered DCF-derived price target to $6 from $12 due to growth in outstanding shares, indicating potential overvaluation concerns.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VOR FAQ
What was Vor Biopharma’s price range in the past 12 months?
Vor Biopharma lowest stock price was $0.63 and its highest was $2.50 in the past 12 months.
What is Vor Biopharma’s market cap?
Vor Biopharma’s market cap is $100.61M.
When is Vor Biopharma’s upcoming earnings report date?
Vor Biopharma’s upcoming earnings report date is Mar 20, 2025 which is in 52 days.
How were Vor Biopharma’s earnings last quarter?
Vor Biopharma released its earnings results on Nov 06, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.402 by $0.002.
Is Vor Biopharma overvalued?
According to Wall Street analysts Vor Biopharma’s price is currently Undervalued.
Does Vor Biopharma pay dividends?
Vor Biopharma does not currently pay dividends.
What is Vor Biopharma’s EPS estimate?
Vor Biopharma’s EPS estimate is -0.29.
How many shares outstanding does Vor Biopharma have?
Vor Biopharma has 68,673,615 shares outstanding.
What happened to Vor Biopharma’s price movement after its last earnings report?
Vor Biopharma reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.402. Following the earnings report the stock price went up 10.256%.
Which hedge fund is a major shareholder of Vor Biopharma?
Among the largest hedge funds holding Vor Biopharma’s share is RA Capital Management. It holds Vor Biopharma’s shares valued at 16M.
---
Vor Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.58 (761.64% Upside)
$12.58 (761.64% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-37.39%
12-Months-Change
Fundamentals
Return on Equity
-90.79%
Trailing 12-Months
Asset Growth
-47.99%
Trailing 12-Months
Company Description
Vor Biopharma
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.
---
VOR Stock 12 Month Forecast
Average Price Target
$12.58
▲(761.64% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering VOR
1 Year
1 Year Success Rate
5/16 ratings generated profit
1 Year Average Return
-23.99%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of -23.99% per trade.
---